Other Developments Adovate, LLC On May 13, 2025, Adial announced that it has received a six-figure development milestone payment from Adovate, LLC, following the commencement of a Phase 1 clinical trial evaluating Adovate's lead compound for asthma, ADO-5030. This milestone payment follows Adovate's exercise of its option to acquire the assets and business of Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, as previously disclosed. Under the terms of the agreement with Adovate, Adial is ...

VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company's poster presented at the European Society for Medical Oncology's ("ESMO") Breast Cancer meeting on May 14-17, 2025, in Munich, Germany. This news release may contain forward-looking statements relating to, among other things, clinical trial results, p ...

Core Insights - Odysight.ai Inc. reported significant growth in revenues and a strong cash position, indicating progress in its business strategy and operational foundations [4][8][3] Financial Performance - Revenues for the three months ended March 31, 2025, were approximately $2.1 million, a substantial increase from $0.2 million in the same period in 2024, primarily due to a contract with a Fortune 500 medical company [4] - Cost of revenues increased to $1.5 million from $0.4 million year-over-year, driven by contract fulfillment costs and inventory impairment [5] - Gross profit was $0.6 million, reflecting a gross margin of 26%, compared to a gross loss of $0.2 million in the prior year [6] - Operating expenses rose to $5.1 million from $3.1 million, largely due to operational expansion and one-time uplisting expenses [7] - The net loss for the quarter was $4.3 million, compared to a net loss of $3.2 million in the same quarter of 2024 [7] Cash Position and Capital Raise - The company had a net cash position of approximately $37.2 million as of March 31, 2025, up from about $17.0 million a year earlier [2][8] - In February 2025, Odysight.ai uplisted to the Nasdaq Capital Market and raised gross proceeds of approximately $23.7 million through a public offering [8][9] Business Developments - The company has established partnerships, including one with Israel Railways to develop an AI-powered visualization system aimed at enhancing railway safety [9] - An initial purchase order was received from a European partner for a combined industrial solution utilizing Odysight.ai's technology [9] Backlog - The backlog as of March 31, 2025, was approximately $14.8 million, indicating future revenue potential [4][16]

Core Insights - IMUNON, Inc. announced promising results from its Phase 1 clinical trial of IMNN-101, a DNA plasmid vaccine utilizing the PlaCCine technology platform, demonstrating better durability and safety compared to mRNA vaccines [1][2][4] Group 1: Clinical Trial Results - The Phase 1 trial involved 24 healthy volunteers and showed that IMNN-101 provided a durable immune response, with a median increase of up to 3-fold in serum neutralizing antibody titers at six months post-vaccination [1][6] - The highest observed increase in neutralizing antibody titers among participants was 8-fold from baseline, indicating a strong immune response [1][4] - IMNN-101 was well tolerated with no serious adverse effects reported, reinforcing its safety profile [1][2] Group 2: Technology and Competitive Advantages - The PlaCCine technology platform offers several advantages, including stability at workable temperatures and ease of manufacturing compared to existing mRNA vaccines [2][5] - IMNN-101 is designed to accommodate single or multiple antigens, providing flexibility in vaccine development [5] - The vaccine demonstrated cross-reactivity against the Omicron XBB1.5 variant and other newer variants, indicating its potential effectiveness against emerging pathogens [4][6] Group 3: Future Development and Strategic Goals - The company is in discussions for further development of the PlaCCine platform for prophylactic vaccines, aiming for long-term strategic partnerships to advance these technologies [2][3] - IMUNON's broader goal is to expand its vaccine toolkit to address unaddressed infectious diseases and reduce hospitalizations [3][8] - The company is also advancing its other clinical programs, including IMNN-001 for advanced ovarian cancer, showcasing its commitment to innovative treatments [7][8]

Core Insights - Akari Therapeutics is focused on developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat various cancer tumors [1][2] - The company appointed Mark Kubik as the new Head of Business Development for Oncology, enhancing its executive team with deep oncology experience [2] - Akari's lead asset, AKTX-101, targets the Trop2 receptor and utilizes the innovative PH1 payload, which is a spliceosome inhibitor designed to induce cancer cell death while activating immune responses [8] Financial Performance - For Q1 2025, Akari reported a net loss of approximately $3.7 million, a decrease from $5.6 million in Q1 2024 [4][16] - Research and development expenses were $0.8 million in Q1 2025, down from $2.3 million in the same period of 2024, primarily due to the suspension of the HSCT-TMA clinical program [4] - General and administrative expenses decreased to approximately $2.7 million in Q1 2025 from $3.7 million in Q1 2024, attributed to reduced legal and professional fees [5] Pipeline and Development Milestones - The company is advancing a pipeline of potentially first-in-class ADC candidates, with significant tumor-killing activity observed in preclinical models [2] - Upcoming milestones include presenting preclinical data on the PH1 payload's immuno-oncology activity at a scientific conference in the second half of 2025 [6] - Akari is exploring preclinical activity for AKTX-101 in various solid tumor indications and seeking strategic partners for research collaborations [6] Cash Position and Funding - As of March 31, 2025, Akari had cash of approximately $2.6 million, with net proceeds from a March 2025 offering totaling around $6.0 million [7] - The company continues efforts to out-license non-core assets in inflammation, ophthalmology, and rare diseases to generate non-dilutive capital for its ADC platform [3]

PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“XAGE”, the “Company”, “we”, “our”, or “us”), today announced the following business updates: 1. Merger Agreement entered with 20/20 BioLabs (“20/20”) Merger Agreement executed on April 11, 2025, pursuant t ...

WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. “We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability,” said Jack Ross, CEO of Synergy. “Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in t ...

IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 20, 2025, at 11:30 am ET. Interested parties can access the live audio webcast for this confere ...

Shenzhen, China, May 15, 2025 (GLOBE NEWSWIRE) -- ZJK Industrial Co. Ltd. (NASDAQ: ZJK) (“ZJK Industrial”, “ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer for artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace and other smart technologies, today announced that it has patented an innovative image recognition-based inspection-control system for carrier tape packaging. Traditional SMT carrier tape inspections rely on manual checks post ...

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer’s dise ...